BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 21092190)

  • 21. A novel gemcitabine derivative-loaded liposome with great pancreas-targeting ability.
    Li PW; Luo S; Xiao LY; Tian BL; Wang L; Zhang ZR; Zeng YC
    Acta Pharmacol Sin; 2019 Nov; 40(11):1448-1456. PubMed ID: 31015736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
    Zagon IS; Jaglowski JR; Verderame MF; Smith JP; Leure-Dupree AE; McLaughlin PJ
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):510-20. PubMed ID: 15947928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer.
    Bunt SK; Mohr AM; Bailey JM; Grandgenett PM; Hollingsworth MA
    Cancer Immunol Immunother; 2013 Feb; 62(2):225-36. PubMed ID: 22864396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells.
    Jacob DA; Bahra M; Langrehr JM; Boas-Knoop S; Stefaniak R; Davis J; Schumacher G; Lippert S; Neumann UP
    J Gastroenterol Hepatol; 2007 May; 22(5):738-48. PubMed ID: 17444865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.
    Leitner S; Sweeney K; Oberg D; Davies D; Miranda E; Lemoine NR; Halldén G
    Clin Cancer Res; 2009 Mar; 15(5):1730-40. PubMed ID: 19223497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Difluoromethylornithine Combined with a Polyamine Transport Inhibitor Is Effective against Gemcitabine Resistant Pancreatic Cancer.
    Gitto SB; Pandey V; Oyer JL; Copik AJ; Hogan FC; Phanstiel O; Altomare DA
    Mol Pharm; 2018 Feb; 15(2):369-376. PubMed ID: 29299930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymeric Micelles of PEG-PLA Copolymer as a Carrier for Salinomycin Against Gemcitabine-Resistant Pancreatic Cancer.
    Daman Z; Montazeri H; Azizi M; Rezaie F; Ostad SN; Amini M; Gilani K
    Pharm Res; 2015 Nov; 32(11):3756-67. PubMed ID: 26228105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer.
    Li YJ; Wu JY; Wang JM; Hu XB; Cai JX; Xiang DX
    Acta Biomater; 2020 Jan; 101():519-530. PubMed ID: 31629893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein.
    Karikari CA; Roy I; Tryggestad E; Feldmann G; Pinilla C; Welsh K; Reed JC; Armour EP; Wong J; Herman J; Rakheja D; Maitra A
    Mol Cancer Ther; 2007 Mar; 6(3):957-66. PubMed ID: 17339366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer.
    Mu GG; Zhang LL; Li HY; Liao Y; Yu HG
    Dig Dis Sci; 2015 Apr; 60(4):1067-80. PubMed ID: 25344906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells.
    Thoennissen NH; Iwanski GB; Doan NB; Okamoto R; Lin P; Abbassi S; Song JH; Yin D; Toh M; Xie WD; Said JW; Koeffler HP
    Cancer Res; 2009 Jul; 69(14):5876-84. PubMed ID: 19605406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
    Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
    Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
    Rajeshkumar NV; Rasheed ZA; García-García E; López-Ríos F; Fujiwara K; Matsui WH; Hidalgo M
    Mol Cancer Ther; 2010 Sep; 9(9):2582-92. PubMed ID: 20660600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapy of Smac mimetic SM-164 in combination with gemcitabine for pancreatic cancer.
    Zhou B; Zhang J; Chen G; You L; Zhang TP; Zhao YP
    Cancer Lett; 2013 Feb; 329(1):118-24. PubMed ID: 23142291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway.
    Wang Y; Zhou Y; Jia G; Han B; Liu J; Teng Y; Lv J; Song Z; Li Y; Ji L; Pan S; Jiang H; Sun B
    Biochem Pharmacol; 2014 Apr; 88(3):322-33. PubMed ID: 24522113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer.
    Jung KH; Yan HH; Fang Z; Son MK; Lee H; Hong S; Hong SS
    Int J Oncol; 2014 Jul; 45(1):311-21. PubMed ID: 24819705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells.
    Zhang Y; Huang Y; Zhang P; Gao X; Gibbs RB; Li S
    Int J Nanomedicine; 2012; 7():4473-85. PubMed ID: 22927761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BH3 Mimetic ABT-199 Enhances the Sensitivity of Gemcitabine in Pancreatic Cancer in vitro and in vivo.
    Zhou Y; Liu H; Xue R; Tang W; Zhang S
    Dig Dis Sci; 2018 Dec; 63(12):3367-3375. PubMed ID: 30155839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
    Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
    Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of heat shock protein 27 (HSP27) increases gemcitabine sensitivity in pancreatic cancer cells through S-phase arrest and apoptosis.
    Guo Y; Ziesch A; Hocke S; Kampmann E; Ochs S; De Toni EN; Göke B; Gallmeier E
    J Cell Mol Med; 2015 Feb; 19(2):340-50. PubMed ID: 25331547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.